An Clinical Study Evaluating the Safety, Tolerability, and efficAcy of HG005 in StaRgardT Disease

Inclusion Criteria: * Patient ≥ 6 and ≤17 years at the time of signing informed consent, with clinical diagnosis of Stargardt disease; * At least one ABCA4 allele on each chromosome; * Both eyes must have well-defined macular atrophic lesions consistent with the diagnosis of Stargardt macular dystrophy. * Meet visual acuity criteria based on ETDRS letter chart * Subject must agree to contraception during the study. * Acceptable hematology, clinical chemistry, urine laboratory, and protocol required eye examination. Exclusion Criteria: * Presence of active intraocular inflammation or uveitis history in either eye; * Presence of ocular or periocular infection history in either eye within 2 weeks prior to selection; * History or presence of corneal dystrophy in the study eye; * History of HIV or hepatitis A, B, or C infection; * Previous treatment with any gene therapy or cell therapy (e.g., stem cell transplantation); * Additional intraocular surgery in study eye 3 months prior to baseline visit; * Participation in an oral therapeutic STGD clinical trial within 3 months (or within 5 half-lives after last dose) prior to Screening * Any concomitant treatment that, in the opinion of the investigator, might interfere with the surgical procedure or healing process of the eye * Any other conditions that would not allow the potential subject to complete follow-up examinations during the study and would, in the opinion of the investigator, make the potential subject unsuitable for the study.